Company performance
Add to research
Current Price
as of Jul 08, 2025$21.33
P/E Ratio
N/A
Market Cap
$1.42B
Description
Add to research
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
Metrics
Add to research
Overview
- HQHampton, NJ
- SectorHealth Technology
- IndustryBiotechnology
- TickerCLDX
- Price$21.33+1.67%
Trading Information
- Market cap$1.42B
- Float97.16%
- Average Daily Volume (1m)1,250,270
- Average Daily Volume (3m)990,013
- EPS-$2.70
Company
- Revenue$7.56M
- Rev growth (1yr)345.51%
- Net income-$53.80M
- Gross margin-24.75%
- EBITDA margin-8,902.45%
- EBITDA-$61.87M
- EV$540.99M
- EV/Revenue71.57
- P/EN/A
- P/S187.32
- P/B2.01
- Debt/Equity0.49
Documents
Add to research
SEC Filings
Factset Street Account